Browse the corpus

Cardiac rhabdomyoma, while benign, represents the most frequently diagnosed heart tumor in infants and children, often serving as an early indicator of tuberous sclerosis complex. The clinical presentation of these tumors can range from being entirely asymptomatic to causing life-threatening complications such as cardiac outflow tract obstruction and severe arrhythmias. Given the spectrum of potential outcomes and the systemic nature of its associated conditions, a comprehensive understanding of cardiac rhabdomyoma is paramount for healthcare professionals. This educational activity thoroughly reviews cardiac rhabdomyoma, beginning with its epidemiology and pathophysiology. Learners are presented with the latest diagnostic techniques, including fetal and postnatal echocardiography and cardiac magnetic resonance imaging, which are critical for accurate identification and monitoring. The course will delve into current management strategies, from a conservative approach of watchful waiting for the common spontaneous regression of these tumors to the implementation of medical therapies with mammalian target of rapamycin inhibitors and, in rare cases, the indications for surgical intervention. By participating in this course, the interprofessional team, including pediatric cardiologists, neonatologists, geneticists, and surgeons, will enhance their competence in collaboratively diagnosing and managing patients with cardiac rhabdomyoma, ensuring well-coordinated and optimal patient care. Objectives: Identify the typical clinical and histopathological features of cardiac rhabdomyoma and its strong association with tuberous sclerosis complex. Evaluate a patient with a cardiac rhabdomyoma for signs of hemodynamic compromise or significant arrhythmia that would necessitate intervention. Apply evidence-based guidelines when selecting a management strategy for cardiac rhabdomyoma, including expectant observation, medical therapy with mammalian target of rapamycin inhibitors, or surgical resection. Collaborate with an interprofessional team, including maternal-fetal medicine specialists, pediatric cardiologists, and genetic counselors, to formulate a comprehensive diagnostic and initial management plan for fetuses and neonates diagnosed with cardiac rhabdomyoma. Access free multiple choice questions on this topic.

Cardiac rhabdomyoma is a rare, benign mesenchymal tumor of striated muscle origin and represents the most common primary cardiac tumor in the pediatric population, typically diagnosed before the age of 1. While rhabdomyomas can occur in both cardiac and extracardiac locations, the extracardiac forms—classified as adult, fetal, and germ cell tumors—most often involve the head and neck.[1] Cardiac rhabdomyomas are histologically regarded as hamartomas and strongly associated with tuberous sclerosis complex, or Bourneville disease. They most frequently arise within the ventricular myocardium, followed by the atria, cavoatrial junction, and epicardial surface in descending order of prevalence. These tumors are often multiple and tend to regress spontaneously, making conservative management appropriate unless symptoms occur. Clinical manifestations result primarily from obstruction of cardiac inflow or outflow tracts, leading to congestive heart failure, or from arrhythmogenic effects. The latter can range from bradycardia due to sinus or atrioventricular (AV) node dysfunction to more complex tachyarrhythmias, including atrial or ventricular tachycardia, AV nodal reentrant tachycardia, and ventricular preexcitation.[2]

Genetic modification during the development of striated muscle may cause rhabdomyoma.[3][4] No other causes have been identified. Between 80% and 90% of cardiac rhabdomyomas are linked to tuberous sclerosis. Surprisingly, only 43% to 67% of neonates with tuberous sclerosis have cardiac rhabdomyomas.[5][6]

Primary cardiac tumors are rare and occur in 0.2% of children.[3] However, cardiac rhabdomyomas are the most common cardiac tumor in children, representing up to 43% in postmortem studies and from 50% to 78% in living cases.[3][4] This tumor is observed in both males and females, with male neonates being slightly more favored by the disease, without any documented proclivity for race.[5]

Cardiac rhabdomyoma is a hamartomatous tumor that typically develops within the myocardium and is most often detectable between 20 and 30 weeks of gestation. Prenatal detection rates have increased with advances in fetal imaging, and these tumors are more frequently identified in fetal than postnatal series. Common sites of involvement include the interventricular septum, both ventricles, and the atrioventricular valves. While cardiac rhabdomyomas can occur sporadically, there is a well-established association with tuberous sclerosis complex (TSC), an autosomal dominant disorder characterized by benign hamartomas in multiple organ systems.[6] TSC is usually diagnosed clinically, with confirmatory genetic testing for pathogenic variants in the TSC1 and TSC2 genes.[7]

On gross examination, rhabdomyomas typically appear as well-demarcated, nonencapsulated nodules that are white, gray, or yellow. Their size ranges widely, from as small as 1 mm up to 10 cm. While they most often arise within the ventricles, affecting the right and left sides equally, these tumors can also be seen in the atria, at the cavoatrial junction, embedded within the papillary muscles, the myocardial wall, the interventricular septum, or even on the epicardial surface. Notably, about 90% of cases involve multiple tumor sites. Although rhabdomyomas are usually intramural, they may extend into the cardiac chambers, sometimes filling an entire chamber and resulting in obstruction of inflow or outflow tracts. Even smaller lesions may involve the conduction system and precipitate arrhythmias.[3][8]Microscopically, rhabdomyomas consist of large, round, or polygonal cells characterized by clear cytoplasm rich in glycogen. The classic “spider cell” appearance is pathognomonic and features a central mass with the nucleus and thin cytoplasmic extensions radiating toward the periphery. Calcification and fibrosis within these tumors are uncommon.[9]

Cardiac rhabdomyoma can often be identified in utero as a cardiac mass using ultrasonography, with fetal echocardiography demonstrating increased sensitivity in detection compared to postnatal imaging.[10][11] Presentation in the fetus can range from incidental findings to serious complications such as heart block, hydrops fetalis, or pericardial effusion.[9] Large tumors may even lead to intrauterine fetal demise. Advances in imaging, including the use of deep learning algorithms like the AVRNet architecture, have shown remarkable accuracy—up to 99.85%—in identifying fetal cardiac rhabdomyomas, enhancing prenatal diagnostic precision. Postnatally, cardiac rhabdomyomas are frequently asymptomatic; however, when symptoms occur, they often relate to arrhythmias or heart failure caused by obstruction of cardiac inflow or outflow tracts. Common presenting complaints include dyspnea, poor feeding, and signs of ventricular dysfunction. Physical examination may reveal murmurs from obstructive effects, irregular rhythms from arrhythmias, or signs of congestive heart failure such as hepatomegaly and respiratory distress. Given the strong association with TSC (Bourneville disease), patients may also exhibit characteristic dermatologic findings such as hypomelanotic “ash leaf” macules, shagreen patches, or facial angiofibromas, which can aid in clinical diagnosis. A thorough family history and examination for these stigmata are important components of patient evaluation.[12]

Evaluation of cardiac rhabdomyoma involves a combination of laboratory, imaging, and electrophysiological studies to confirm the diagnosis, assess tumor characteristics, and identify associated conditions such as TSC. Given the strong correlation between cardiac rhabdomyoma and TSC, genetic testing for TSC1 and TSC2 mutations is recommended to support diagnosis and guide family counseling. A baseline 12-lead electrocardiogram (EKG) is essential at diagnosis—even in asymptomatic patients—to detect conduction abnormalities or arrhythmias, with routine follow-up EKGs every 2 to 5 years. Holter or event monitoring may be necessary if intermittent arrhythmias are suspected. The imaging modality of choice for diagnosis and follow-up is pediatric transthoracic echocardiography, which typically reveals multiple echogenic nodular masses embedded within the ventricular myocardium. These tumors may also protrude into the ventricular cavity. Atypical presentations, such as a single large tumor or involvement of the atria, can mimic other cardiac tumors like atrial myxoma, potentially complicating diagnosis. Cardiac magnetic resonance imaging is a valuable adjunct when echocardiographic findings are unclear, offering superior delineation of tumor margins, more accurate assessment of ventricular systolic function, and aiding surgical planning when resection is considered.[9] Additional radiographic studies, such as chest x-rays, may reveal cardiomegaly or pulmonary congestion but are nonspecific. A comprehensive approach combining clinical, genetic, EKG, and advanced imaging assessments is critical to optimizing diagnosis, management, and long-term surveillance of patients with cardiac rhabdomyoma.

Cardiac rhabdomyomas are asymptomatic and regress spontaneously. In rare instances of hemodynamic compromise and congestive heart failure, pharmacotherapy with angiotensin-converting enzyme inhibitors, digitalis, and diuretics is indicated. Prostaglandin E1 can manage hemodynamic instability in critically ill newborns with ventricular outflow obstruction. Prostaglandin E1 infusion keeps the arterial duct open and allows systemic and pulmonary blood mixing. Oral mammalian target of rapamycin (mTOR) inhibitors, such as sirolimus and everolimus, are increasingly used as the primary treatment for rhabdomyomas. Multiple case reports document the successful use of mTOR inhibitors to treat life-threatening cardiac rhabdomyomas in infants, often associated with TSC. A 2023 systematic review pooled 31 reports (48 patients) and found that everolimus, in 83% of cases, or sirolimus shrank cardiac rhabdomyomas by an average of 57%, with improvement in hemodynamic status in most infants. Median therapy duration was 2 months. Common adverse effects were manageable.[13] In 1 notable case study, transplacental sirolimus reduced fetal cardiac rhabdomyoma considerably through maternal oral intake.[14] mTOR inhibitors are traditionally known for halting the multiplication of T- and B-lymphocytes and preventing in-stent restenosis, which is why they are used in transplant and angioplasty. Their mechanism of action is through binding to the FK-binding protein 12, forming a complex that disrupts the mTOR enzyme, a key regulator of cell growth in G phase, that functions as a central node in eukaryotic cell signaling, and integrates a vast array of intracellular and extracellular cues. mTOR inhibitors have been used in cardiothoracic trials for delaying pulmonary vein stenosis and the treatment of primary lung and cardiac cancers.[15][16] While effective, these medications carry cardiovascular risks; patients may experience hypertension, edema, and high cholesterol or triglyceride levels.[17] Additionally, they can lead to electrolyte disturbances like hypokalemia.[18][19]

mTOR inhibitors are traditionally known for halting the multiplication of T- and B-lymphocytes and preventing in-stent restenosis, which is why they are used in transplant and angioplasty. Their mechanism of action is through binding to the FK-binding protein 12, forming a complex that disrupts the mTOR enzyme, a key regulator of cell growth in G phase, that functions as a central node in eukaryotic cell signaling, and integrates a vast array of intracellular and extracellular cues. mTOR inhibitors have been used in cardiothoracic trials for delaying pulmonary vein stenosis and the treatment of primary lung and cardiac cancers.[15][16] While effective, these medications carry cardiovascular risks; patients may experience hypertension, edema, and high cholesterol or triglyceride levels.[17] Additionally, they can lead to electrolyte disturbances like hypokalemia.[18][19] Antiarrhythmics are useful when conduction defects or other ventricular arrhythmias are present. Partial or complete surgical resection of the mass is indicated in cases of hemodynamic compromise and congestive heart failure due to a large tumor.[20] Partial resection is preferred if there is a high risk of damage to the myocardial mass or vital structure by complete excision.[21] Orthotopic heart transplantation is considered in infrequent occasions when the tumor is so large that it has replaced the normal myocardial tissue. If the patient can not tolerate the long waiting times for a heart transplant, single ventricle palliation, artificial heart, or left ventricle assist devices can be performed as a bridge to transplant or total correction.

The differential diagnosis includes: Cardiac fibroma This condition is associated with Gorlin syndrome. MRI shows a low T2 signal and intense late gadolinium enhancement due to fibrous content; calcification signs on CT scans help differentiate it from rhabdomyoma. Microscopic examination would reveal dense collagen, spindle-shaped fibroblasts, and possibly entrapped cardiomyocytes. Atrial myxoma This is usually not embedded in the myocardium; instead, stalked or pedunculated, with a tendency to attach to the interatrial septum from the left atrial chamber side. Histologically, myxoid stroma is abundant with dispersed stellate cells. Hemangioma The transthoracic echocardiogram shows it as echogenic with prominent blood flow. MRI reveals a high T2 signal with intense contrast enhancement due to vascularity. Teratoma Rare, predominantly in fetuses and newborns, sometimes part of a congenital cystic mediastinal teratoma. Contains tissues from all 3 germ layers (eg, cartilage, neural tissue, epithelium). Thrombus This is a nontumorous mass that is common in adults with atrial fibrillation, left ventricular dysfunction, or aneurysm. On imaging, it may appear echolucent or laminated, avascular on Doppler or contrast imaging, and nonenhanced and layered on CT or MRI. Inflammatory myofibroblastic tumor This condition is sporadic and can affect people of any age. Cardiac inflammatory myofibroblastic tumors constitute a small subset of inflammatory pseudotumors. On imaging, they appear as a solid mass, often heterogeneous, with variable enhancement. They can mimic malignant lesions. Histologically, they show myofibroblastic spindle cells with inflammatory infiltrates (plasma cells, lymphocytes). Anaplastic lymphoma kinase is positive in 50% of cases.

The patients who have had surgery for the removal of rhabdomyoma have a fair to good prognosis. The highest risk is among cardiac rhabdomyomas. They may grow and obstruct the left ventricular outflow tract, thus causing abnormalities in the flow, or may cause ventricular tachycardias or heart blocks.[9] The presence of fetal cardiac rhabdomyoma may be a sign of tuberous sclerosis, and thus, other structures should be evaluated, ie, the renal or brain parenchyma for tumors; this is because cardiac rhabdomyoma is often the first symptom of tuberous sclerosis, followed by neurological involvement and impairment.[22]

Deterrence and patient education for cardiac rhabdomyoma focus on early detection, ongoing monitoring, and comprehensive counseling, especially given the tumor’s strong association with TSC. Families should be educated about the genetic basis of TSC, inheritance patterns, and the value of genetic counseling for at-risk relatives. Because many cardiac rhabdomyomas regress spontaneously during infancy or early childhood, parents should be counseled on the typically favorable natural history while being made aware of possible complications such as arrhythmias, obstruction, or heart failure. Education should also address the importance of regular follow-up with pediatric cardiology, including periodic echocardiograms and electrocardiograms, even if the child is asymptomatic. Families should be instructed to promptly report symptoms such as cyanosis, feeding difficulty, lethargy, syncope, or seizures, as these may signal acute cardiac or neurologic events. Given the systemic manifestations of TSC, multidisciplinary care involving cardiology, neurology, dermatology, nephrology, and genetics should be emphasized to ensure early recognition and management of extracardiac lesions. Finally, anticipatory guidance should include discussions on activity restrictions, surgical considerations in case of hemodynamic compromise, and available patient advocacy or support networks.

Patients diagnosed with cardiac rhabdomyoma, particularly neonates and infants, often present complex clinical scenarios requiring timely diagnosis, individualized treatment, and coordinated long-term care. Although most cardiac rhabdomyomas regress spontaneously, symptomatic cases, such as those causing outflow tract obstruction or life-threatening arrhythmias, necessitate the involvement of a multidisciplinary team to determine optimal interventions. Pediatric cardiologists, congenital cardiothoracic surgeons, neonatologists, geneticists, advanced practice clinicians, radiologists, pharmacists, and nurses all play critical roles in accurately diagnosing, monitoring, and managing these cases. Familiarity with echocardiographic findings, cardiac MRI interpretation, and genetic associations, especially with tuberous sclerosis complex, is essential. Integrating promising therapies, such as mTOR inhibitors, requires pharmacist oversight for dosing and adverse event monitoring. At the same time, nurses and advanced clinicians support parental education and longitudinal monitoring and care. The healthcare team must implement a structured, evidence-based care strategy grounded in shared decision-making and ethical practice to enhance outcomes. Interprofessional communication is crucial, particularly during transitions from prenatal diagnosis to neonatal care or medical therapy to surgical consultation. Regular interdisciplinary case reviews and coordinated care pathways ensure that each specialist contributes expertise to the collective management plan. Genetic counseling, developmental assessments, and psychosocial support services reinforce holistic, patient-centered care. Through seamless collaboration, role clarity, and strategic coordination, the interprofessional team can optimize therapeutic outcomes, reduce complications, and improve quality of life for patients with cardiac rhabdomyoma and their families